Network pharmacology: New guidelines for drug discovery

Yaoxue Xuebao

Volumn 45, Issue 12, 2010, Pages 1472-1477

  Liu, Ai Lin ^a   Du, Guan Hua ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Disease drug network; Drug discovery; Network computational approach; Network pharmacology

Indexed keywords

CHINESE MEDICINE; COMPUTER ANALYSIS; DRUG DEVELOPMENT; MEDICAL RESEARCH; NETWORK PHARMACOLOGY; PRACTICE GUIDELINE; REVIEW;

ALGORITHMS; ANIMALS; COMPUTATIONAL BIOLOGY; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG INTERACTIONS; HUMANS; MEDICINE, CHINESE TRADITIONAL; SOFTWARE; SYSTEMS BIOLOGY;

EID: 78650633862     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Du GH. High-throughput Drug Screening [M]. Beijing: Chemical Industry Press, 2002.
2. Hopkins AL. Network pharmacology: the next paradigm in drug discovery [J]. Nat Chem Biol, 2008, 4: 682-690.
3. Hughes B. 2008 FDA drug approvals [J]. Nat Rev Drug Discov, 8: 93-96.
4. Pan JH. New paradigm for drug discovery based on network pharmacology [J]. Chin J New Drugs Clin Rem, 2009, 28: 721-726.
5. Zhen YS. Research and Development of Anticancer Drugs [M]. Beijing: Chemical Industry Press, 2004.
6. Cohn L.J. Torcetrapib and coronary events [J]. N Engl J Med, 2008, 358: 1863-1864.
7. Tardif J.-C. McMurray J.J. Klug E. Small R. Schumi J. Choi J. Cooper J. Scott R. Lewis E.F. L'Allier P.L. Pfeffer M.A. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial The Lancet 2008 371 9626 1761-1768 DOI 10.1016/S0140-6736(08)60763-1, PII S0140673608607631 [7] Tardif JC, McMurray JJ, Klug E, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial [J]. Lancet, 2008, 371: 1761-1768. (Pubitemid 351697951)
8. Hawker GA, Katz JN, Solomon DH. The patient's perspective on the recall of Vioxx [J]. J Rheumatol, 2006, 33: 1082-1088.
9. Chyau J. Casting a global safety net-a framework for food safety in the age of globalization [J]. Food Drug Law J, 2009, 64:313-334.
10. Yildirim MA, Goh KI, Cusick ME, et al. Drug-target network [J]. Nat Biotechnol, 2007, 25: U19-U26.
11. Dyer M.R. Cohen D. Herrling P.L. Functional genomics: From genes to new therapies Drug Discovery Today 1999 4 3 109-114 DOI 10.1016/S1359-6446(99)01310- 0, PII S1359644699013100 [11] Dyer MR, Cohen D, Herrling PL. Functional genomics: from genes to new therapies [J]. Drug Discov Today, 1999, 4: 109-114. (Pubitemid 29414827)
12. Cho WC. Proteomics technologies and challenges [J]. Genomics Proteomics Bioinformatics, 2007, 5: 77-85.
13. Friboulet A, Thomas D. Systems biology-an interdisciplinary approach [J]. Biosens Bioelectron, 2005, 20: 2404-2407.
14. Metz JT, Hajduk PJ. Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks [J]. Curr Opin Chem Biol, 2010, 14: 498-504.
15. Goh KI, Cusick ME, Valle D, et al. The human disease network [J]. Proc Natl Acad Sci USA, 2007, 104: 8685-8690.
16. Zambrowicz BP, Sands AT. Modeling drug action in the mouse with knockouts and RNA interference [J]. Drug Discov Today Targets, 2004, 3: 198-207.
17. Winzeler EA, Shoemaker DD, Astromoff A, et al. Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis [J]. Science, 1999, 285: 901-906.
18. Giaever G, Chu AM, Ni L, et al. Functional profiling of the Saccharomyces cerevisiae genome [J]. Nature, 2002, 418: 387-391.
19. Deutschbauer A.M. Jaramillo D.F. Proctor M. Kumm J. Hillenmeyer M.E. Davis R.W. Nislow C. Giaever G. Mechanisms of haploinsufficiency revealed by genome-wide profiling in yeast Genetics 2005 169 4 1915-1925 DOI 10.1534/genetics.104.036871 [19] Deutschbauer AM, Jaramillo DF, Proctor M, et al. Mechanisms of haploinsufficiency revealed by genome-wide profiling in yeast [J]. Genetics, 2005,169: 1915-1925. (Pubitemid 40695608)
20. Hopkins AL, Groom CR. The draggable genome [J]. Nat Rev Drug Discov, 2002, 1:727-730.
21. Austin CP, Battey JF, Bradley A, et al. The knockout mouse project [J]. Nat Genet, 2004,36: 921-924.
22. Zambrowicz BP, Turner CA, Sands AT. Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry [J]. Curr Opin Pharmacol, 2003, 3: 563-570.
23. Zambrowicz BP, Sands AT. Knockouts model the 100 best-selling drugs-will they model the next 100? [J]. Nat Rev Drug Discov, 2003, 2: 38-51.
24. Kitano H. Towards a theory of biological robustness [J]. Mol Syst Biol, 2007, 3: 137.
25. Barabási AL, Oltvai ZN. Network biology: understanding the cell's functional organization [J]. Nat Rev Genet, 2004, 5: 101-113.
26. Albert R. Jeong H. Barabasi A.-L. Error and attack tolerance of complex networks Nature 2000 406 6794 378-382 DOI 10.1038/35019019 [26] Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks [J]. Nature, 2000, 406: 378-382. (Pubitemid 30625551)
27. Csermely P. Agoston V. Pongor S. The efficiency of multi-target drugs: The network approach might help drug design Trends in Pharmacological Sciences 2005 26 4 178-182 DOI 10.1016/j.tips.2005.02.007 [27] Csermely P, Agoston V, Pongor S. The efficiency of multitarget drugs: the network approach might help drug design [J]. Trends Pharmacol Sci, 2005, 26: 178-182. (Pubitemid 40432652)
28. Korcsmáros T, Szalay MS, Böde C, et al. How to design multitarget drugs: target search options in cellular networks [J]. Expert Opin Drug Discov, 2007, 2: 1-10.
29. Ooi S.L. Pan X. Peyser B.D. Ye P. Meluh P.B. Yuan D.S. Irizarry R.A. Bader J.S. Spencer F.A. Boeke J.D. Global synthetic-lethality analysis and yeast functional profiling Trends in Genetics 2006 22 1 56-63 DOI 10.1016/j.tig.2005.11.003, PII S016895250500332X [29] Ooi SL, Pan X, Peyser BD, et al. Global synthetic-lethality analysis and yeast functional profiling [J]. Trends Genet, 2006, 22: 56-63. (Pubitemid 43011998)
30. Hillenmeyer M.E. Fung E. Wildenhain J. Pierce S.E. Hoon S. Lee W. Proctor M. St.Onge R.P. Tyers M. Koller D. Altman R.B. Davis R.W. Nislow C. Giaever G. The chemical genomic portrait of yeast: Uncovering a phenotype for all genes Science 2008 320 5874 362-365 DOI 10.1126/science.1150021 [30] Hillenmeyer ME, Fung E, Wildenhain J, et al. The chemical genomic portrait of yeast: uncovering a phenotype for all genes [J]. Science, 2008, 320: 362-365. (Pubitemid 351555656)
31. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia [J]. Nat Rev Drug Discov, 2004, 3: 353-359.
32. Wermuth CG Multitarget drugs: the end of the 'one-targetone-disease' philosophy ? [J]. Drug Discov Today, 2004, 9: 826-827.
33. Keith CT, Borisy AA, Stockwel BR. Multicomponent therapeutics for networked systems [J]. Nat Rev Drug Discov, 2005, 4: 71-78.
34. Petrelli A. Giordano S. From single- to multi-target drugs in cancer therapy: When aspecificity becomes an advantage Current Medicinal Chemistry 2008 15 5 422-432 http://www.ingentaconnect.com/content/ben/cmc/2008/00000015/ 00000005/art00001 DOI 10.2174/092986708783503212 [34] Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage [J]. Curr Med Chem, 2008, 15: 422-432. (Pubitemid 351472408)
35. Mencher SK, Wang LG Promiscuous drugs compared to selective drugs (promiscuity can be a virtue) [J]. BMC Clin Pharmacol, 2005, 5: 3.
36. Hopkins AL, Mason JS, Overington JP. Can we rationally design promiscuous drugs ? [J]. Curr Opin Struct Biol, 2006, 16: 127-136.
37. Flordellis C.S. Manolis A.S. Paris H. Karabinis A. Rethinking target discovery in polygenic diseases Current Topics in Medicinal Chemistry 2006 6 16 1791-1798 http://www.ingentaconnect.com/content/ben/ctmc/2006/00000006/00000016/ art00009 DOI 10.2174/156802606778194226 [37] Flordellis CS, Manolis AS, Paris H, et al. Rethinking target discovery in polygenic diseases [J]. Curr Top Med Chem, 2006, 6: 1791-1798. (Pubitemid 44323063)
38. Dessalew N, Workalemahu M. On the paradigm shift towards multitarget selective drug design [J]. Curr Comput Aided Drug Des, 2008, 4: 76-90.
39. Keskin O. Gursoy A. Ma B. Nussinov R. Towards drugs targeting multiple proteins in a systems biology approach Current Topics in Medicinal Chemistry 2007 7 10 943-951 http://www.ingentaconnect.com/content/ben/ctmc/2007/00000007/ 00000010/art00004 DOI 10.2174/156802607780906690 [39] Keskin O, Gursoy A, Ma B, et al. Towards drugs targeting multiple proteins in a systems biology approach [J]. Curr Top Med Chem, 2007, 7: 943-951. (Pubitemid 47040521)
40. Zimmermann G.R. Lehar J. Keith C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts Drug Discovery Today 2007 12 1 2 34-42 DOI 10.1016/j.drudis.2006.11.008, PII S1359644606004697 [40] Zimmermann GR, Lehar J, Keith CT. Multi-target therapeutics: when the whole is greater than the sum of the parts [J]. Drug Discov Today, 2007, 12: 34-42. (Pubitemid 46014485)
41. Vanunu O, Magger O, Ruppin E, et al. Associating genes and protein complexes with disease via network propagation [J]. PLoS Comput Biol, 2010, 6: e1000641.
42. Li Y, Patra JC. Genome-wide inferring gene-phenotype relationship by walking on the heterogeneous network [J]. Bioinformatics, 2010,26: 1219-1224.
43. Wu X. Jiang R. Zhang M.Q. Li S. Network-based global inference of human disease genes Molecular Systems Biology 2008 4 189 DOI 10.1038/msb.2008.27, PII MSB200827 [43] Wu X, Jiang R, Zhang MQ, et al. Network-based global inference of human disease genes [J]. Mol Syst Biol, 2008, 4: 189. (Pubitemid 351655223)
44. Nibbe RK, Koyutuk M, Chance MR. An integrative-omics approach to identify functional sub-networks in human colorectal cancer [J]. PLoS Comput Biol, 2010, 6: e1000639.
45. Hu G, Agarwal P. Human disease-drag network based on genomic expression profiles [J]. PLoS One, 2009,4: e6536.
46. Yan AC, Smolinski KN. Melanocytic nevi: challenging clinical situations in pediatric dermatology [J]. Adv Dermatol, 2005, 21:65-80.
47. König R, Stertz S, Zhou Y, et al. Human host factors required for influenza virus replication [J]. Nature, 2010, 463: 813-817.
48. Goh KI, Cusick ME, Valle D, et al. The human disease network [J]. Proc Natl Acad Sci USA, 2007, 104: 8685-8690.
49. He FY, Deng KW, Shi JL, et al. Several basic bottleneck problems about the technology research on the prescription of effective components group of traditional Chinese medicines and the proposed ideas of mathematical characterization [J]. J Chin Med Mater, 2009, 32: 1-7.
50. Du GH. Overview of effective compounds group formulaion in traditional Chinese medical prescription [J]. Chin Tradit Pat Med, 2002, 24: 878-880.
51. Du GH, Wang YH, Zhang R, et al. Multi-target and multicomponent pattern, a superficial understanding of the action mechanism of traditional Chinese medicine [J]. World Sci Technol Mod Tradit Chin Med, 2009, 11: 480-484.
52. Wang YH, Du GH. Effective components combination of Xiaoxuming Decoction on anti-Alzheimer's disease [J]. Chin Tradit Pat Med, 2005, 27: 993-996.
53. Zhang R, Dai Y, Cheng XR. Research on the antithrombotic effect and the action mechanism of the effective components group of Xiao Shuan Tong Luo prescription [J]. Chin Tradit Pat Med , 2006, 28: 1479-1481.